カテゴリ： GlobalData, アメリカ, 企業調査

National Comprehensive Cancer Network：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：National Comprehensive Cancer Network - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9314
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
National Comprehensive Cancer Network (NCCN) is a not-for-profit cancer center that offers patient care, research, and education services. The center offers research and medical information to help patients and health professionals related to cancer care. It provides subscriptions and products which include NCCN flash updates, NCCN drugs and biologic compendium, NCCN chemotherapy order templates, NCCN trends and NCCN academy video modules, among others. NCCN also offers accredited educational opportunities and tools; conferences and congresses. The center’s research areas include oncology pre clinical, translation and clinical research. It caters its services to patients, clinicians and health care decision-makers. NCCN is headquartered in Philadelphia, Pennsylvania, the US.

National Comprehensive Cancer Network – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Licensing Agreements 27
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network – Key Competitors 35
National Comprehensive Cancer Network – Key Employees 36
National Comprehensive Cancer Network – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Government and Public Interest 39
Sep 11, 2018: New Guidelines Provide Vital Information for Women Diagnosed with the Most Common Type of Gynecologic Cancer 39
Aug 09, 2018: NCCN publishes first-ever U.S. guidelines for rare cancers associated with pregnancy 40
Jul 23, 2018: New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40 41
Apr 26, 2018: New Translations of NCCN Guidelines for Patients Advance Global Mission to Empower People with Cancer 42
Apr 18, 2018: New Study Shows Why Cancer Cost Planning Needs to Start Accounting for People Under 65 43
Apr 04, 2018: NCCN Helps Strengthen Cancer Research Pipeline by Awarding Grants to Five Young Investigators 44
Mar 29, 2018: National Comprehensive Cancer Network Honors Key Contributors to the Improvement of Global Cancer Care and Dedication to the NCCN Mission 45
Mar 13, 2018: Testicular Cancer Survivors Need Adequate Screening for Long Term Heart Disease Risks 46
Feb 27, 2018: New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes 47
Jan 31, 2018: NCCN Reaches New Records for Guidelines, Resources, and Programs 49
Jan 25, 2018: NCCN Imaging Appropriate Use Criteria Endorsed by Intermountain Healthcare and Will be Included in the Intermountain AUC for Lung Cancer 50
Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 51
Dec 01, 2017: Advocates Reveal Cancer Survivorship Challenges and Resources during National Comprehensive Cancer Network’s Patient Advocacy Summit 52
Nov 29, 2017: National Comprehensive Cancer Network Introduces New Guidelines for Patients with a Form of Cancer Associated with HIV and AIDS 53
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 54
Sep 27, 2017: Study Finds “Standard Care” Treatments in Breast Cancer Clinical Trials Not Always Standard 55
Aug 11, 2017: New NCCN Patient Resources for Rectal Cancer Now Available 56
May 19, 2017: NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways 57
Other Significant Developments 58
Sep 17, 2018: New Benchmarking Tool for Measuring Development and Organization of Integrated Practice Units Published in Journal of the National Comprehensive Cancer Network 58
Jun 21, 2018: New Study in JNCCN Raises Questions about Resource Availability at Hospitals on Weekends and Holidays 59
May 14, 2018: New Tool Helps People with Leukemia Better Understand Their Treatment Options 60
Apr 10, 2018: NCCN Provides New, Free Database to Assist in Cancer Research Collaborations 61
Mar 28, 2018: Nearly Two Thousand Cancer Experts Come Together to Discuss Ways to Improve Quality, Effectiveness, and Efficiency of Care 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network, Key Competitors 35
National Comprehensive Cancer Network, Key Employees 36
National Comprehensive Cancer Network, Subsidiaries 38

List of Figures
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[National Comprehensive Cancer Network：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Australian Securities & Investments Commission：企業の戦略的SWOT分析
    Australian Securities & Investments Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Nomura Holdings, Inc.：企業の戦略・SWOT・財務情報
    Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Middleby Corporation (MIDD)：企業の財務・戦略的SWOT分析
    The Middleby Corporation (MIDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Vior Inc (VIO)：企業の財務・戦略的SWOT分析
    Summary Vior Inc (Vior) is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold and silver metal properties in North and Latin America. Its projects comprise Mosseau Gold project, Foothills Rutile project, Vezza-Noyard Go …
  • Myriad RBM Inc-医療機器分野：企業M&A・提携分析
    Summary Myriad RBM Inc (Myriad RBM), formerly Rules Based Medicine Inc, a subsidiary of Myriad Genetics Inc, is an immunoassay testing laboratory that provides protein biomarker products and services. The company’s products and services include HumanMAP services that assist investigators in the disc …
  • Yoshinoya Holdings Co Ltd
    Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sul America SA：企業の戦略・SWOT・財務情報
    Sul America SA - Strategy, SWOT and Corporate Finance Report Summary Sul America SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • K-Electric Ltd (KEL)：企業の財務・戦略的SWOT分析
    K-Electric Ltd (KEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Daito Trust Construction Co., Ltd.
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • International Stem Cell Corp (ISCO)：企業の財務・戦略的SWOT分析
    Summary International Stem Cell Corp (ISCC) is a clinical stage biotechnology company that develops stem cell technology solutions. The company develops parthenogenesis, a stem cell technology that improves the field of regenerative medicine. It provides stem cells such as embryonic stem cells, adul …
  • Travelport Limited (TVPT)：企業の財務・戦略的SWOT分析
    Travelport Limited (TVPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Immunovia AB (IMMNOV)：医療機器：M&Aディール及び事業提携情報
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Citizens Electric Corporation：発電所・企業SWOT分析
    Citizens Electric Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Paychex, Inc.：企業の戦略・SWOT・財務情報
    Paychex, Inc. - Strategy, SWOT and Corporate Finance Report Summary Paychex, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tieto Corporation：企業のM&A・事業提携・投資動向
    Tieto Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tieto Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Hotel Leela Venture Limited：戦略・SWOT・企業財務分析
    Hotel Leela Venture Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Leela Venture Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Warner Media LLC.：企業の戦略・SWOT・財務分析
    Warner Media LLC. - Strategy, SWOT and Corporate Finance Report Summary Warner Media LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NCC Ltd (NCC)：企業の財務・戦略的SWOT分析
    NCC Ltd (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Takenaka Corporation：企業の戦略・SWOT・財務情報
    Takenaka Corporation - Strategy, SWOT and Corporate Finance Report Summary Takenaka Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SecureWorks Corp (SCWX)：企業の財務・戦略的SWOT分析
    SecureWorks Corp (SCWX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆